Vertex Pharmaceuticals has two clinical-stage programs for type 1 diabetes, each employing different methods for preventing the immune system from rejecting the cell therapies. For a third program in ...
Scientists have successfully transplanted gene-edited insulin-producing cells into a man with type 1 diabetes—allowing him to ...
-Vertex to receive non-exclusive rights to CRISPR Therapeutics’ CRISPR/Cas9 to accelerate development of potentially curative cell therapies for T1D- BOSTON & ZUG, Switzerland--(BUSINESS WIRE)--Vertex ...
CRISPR Therapeutics (NASDAQ:CRSP) said Monday that Vertex Pharmaceuticals (VRTX) subsidiary ViaCyte has elected to opt-out of their development partnership for gene-edited stem cell therapies for the ...
CRISPR Therapeutics CRSP, along with partner ViaCyte, announced that Health Canada has approved the clinical trial application for its investigational allogeneic stem cell-derived therapy, VCTX210.
Who invented CRISPR 2.0? What happens when a drug company actually lowers prices? And is Novavax going to survive? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast.
Vertex Therapeutics VRTX announced that it is entering into a new non-exclusive licensing agreement with CRISPR Therapeutics CRSP for the use of the latter’s gene-editing technology, CRISPR/Cas9. The ...
Vertex Pharmaceuticals said today it has agreed to acquire ViaCyte for $320 million cash, in a deal that bolsters the buyer’s diabetes pipeline with ViaCyte’s triple-pronged attack against the disease ...
-Vertex to receive non-exclusive rights to CRISPR Therapeutics' CRISPR/Cas9 to accelerate development of potentially curative cell therapies for T1D- -CRISPR Therapeutics to receive $100M upfront ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback